Spontal-N: A Corpus of Interactional Spoken Norwegian

Spontal-N is a corpus of spontaneous, interactional Norwegian. To our knowledge, it is the first corpus of Norwegian in which the majority of speakers have spent significant parts of their lives in Sweden, and in which the recorded speech displays varying degrees of interference from Swedish. The corpus consists of studio quality audio- and video-recordings of four 30-minute free conversations between acquaintances, and a manual orthographic transcription of the entire material. On basis of the orthographic transcriptions, we automatically annotated approximately 50 percent of the material on the phoneme level, by means of a forced alignment between the acoustic signal and pronunciations listed in a dictionary. Approximately seven percent of the automatic transcription was manually corrected. Taking the manual correction as a gold standard, we evaluated several sources of pronunciation variants for the automatic transcription. Spontal-N is intended as a general purpose speech resource that is also suitable for investigating phonetic detail

Implementing and evaluating a multimodal and multilingual tourist guide

Contains fulltext : 75069.pdf (author's version ) (Open Access)International CLASS Workshop on Natural, Intelligent and Effective Interaction in Multimodal Dialogue Systems, 28 juni 200

The MUST guide to Paris: Implementation and expert evaluation of a multimodal tourist guide to Paris

Contains fulltext : 75061.pdf (author's version ) (Open Access)17 juni 20023 p

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

Patient-reported outcomes (PROs), such as symptoms, functioning, and other health-related quality-of-life concepts are gaining a more prominent role in the benefit–risk assessment of cancer therapies. However, varying ways of analysing, presenting, and interpreting PRO data could lead to erroneous and inconsistent decisions on the part of stakeholders, adversely affecting patient care and outcomes. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI) Consortium builds on the existing SISAQOL work to establish recommendations on design, analysis, presentation, and interpretation for PRO data in cancer clinical trials, with an expanded set of topics, including more in-depth recommendations for randomised controlled trials and single-arm studies, and for defining clinically meaningful change. This Policy Review presents international stakeholder views on the need for SISAQOL-IMI, the agreed on and prioritised set of PRO objectives, and a roadmap to ensure that international consensus recommendations are achieved